Although there are no well-defined points of molecular distinction, clinical and genetic studies divide AD into early-onset AD associated with molecular modifications of APP, PSEN1 and PSEN2 (Wan et al., 2020) and the late-onset AD that is mainly associated with risk variants in the APOE gene, while recently, 75 genes are reported as risk factors in multi-ethnic studies of AD (Bellenguez et al., 2022). This evidence concerns the gene APOE and Alzheimer disease.